current
advent
molecular
technolog
togeth
multidisciplinari
interplay
sever
field
led
develop
genom
concentr
detect
pathogen
event
genom
level
structur
function
genom
approach
pinpoint
technic
challeng
explor
diseaserel
gene
recognit
structur
alter
elucid
gene
function
variou
promis
technolog
diagnost
applic
structur
genom
current
prepar
larg
databas
diseasegen
genet
alter
etc
mutat
scan
dna
chip
technolog
function
genom
also
explor
express
genet
hybrid
pcrand
sequencebas
technolog
twohybrid
technolog
next
gener
sequenc
bioinformat
comput
biolog
advanc
microarray
chip
technolog
microarray
allow
parallel
analysi
gene
express
pattern
thousand
gene
simultan
sequenc
inform
collect
genom
mani
individu
lead
rapid
discoveri
singl
nucleotid
polymorph
snp
advanc
genet
engin
also
revolution
immunoassay
biotechnolog
via
engin
antibodyencod
gene
phage
display
technolog
biotechnolog
play
import
role
develop
diagnost
assay
respons
outbreak
critic
diseas
respons
need
howev
also
need
pinpoint
variou
obstacl
issu
relat
commerci
widespread
dispers
genet
knowledg
deriv
exploit
biotechnolog
industri
develop
market
diagnost
servic
implement
genet
criteria
patient
select
individu
assess
risk
benefit
treatment
emerg
major
challeng
pharmaceut
industri
thu
field
revolution
current
era
may
open
new
vista
field
diseas
manag
healthcar
system
critic
crucial
depend
upon
diagnost
today
medic
decis
make
strongli
base
upon
diagnost
result
right
genet
test
help
notifi
person
cancer
treatment
microbi
cultur
recognit
right
antibiot
combat
infect
diagnost
provid
critic
insight
everi
stage
medic
care
prevent
detect
diagnosi
treatment
success
manag
health
condit
main
categori
diagnost
clinic
chemistri
immunolog
hematolog
microbiolog
molecular
diagnost
molecular
diagnost
attract
particular
attent
recent
year
owe
deep
insight
bring
diagnosi
treatment
molecular
diagnost
transform
diagnost
dynam
lead
insight
research
treatment
mani
diseas
state
revolution
health
care
current
review
provid
overview
current
scenario
molecular
diagnost
glimps
key
technolog
drive
molecular
revolut
pinpoint
specif
diseas
disord
conclud
note
emerg
two
novel
therapeut
approach
pharmacogenom
nutrigenom
power
influenc
diseas
manag
plan
field
molecular
biolog
grew
late
twentieth
centuri
tabl
advis
prenat
genet
test
thalassemia
base
dna
sequenc
restrict
enzym
cut
dna
specif
short
sequenc
creat
variou
band
dna
strand
depend
upon
presenc
allel
genet
variat
term
molecular
diagnost
util
name
compani
molecular
diagnost
incorpor
bethesda
research
laboratori
molecular
diagnost
saw
era
identif
newli
discov
gene
new
techniqu
dna
sequenc
led
emerg
distinct
field
molecular
genom
laboratori
medicin
associ
molecular
patholog
amp
form
give
structur
amp
cofound
journal
medic
diagnost
informa
healthcar
launch
expert
review
medic
diagnost
onward
hap
map
project
combin
inform
onelett
genet
differ
recur
human
popul
singl
nucleotid
polymorph
snp
also
point
relationship
diseas
molecular
diagnost
techniqu
thalassemia
use
genet
hybrid
test
recogn
specif
snp
caus
individu
diseas
commerci
techniqu
debut
patentsexclus
right
achiev
european
union
direct
clarifi
patent
dna
sequenc
allow
exampl
patent
use
molecular
diagnost
seen
us
amp
su
myriad
genet
defi
latter
patent
regard
two
gene
associ
breast
cancer
howev
us
suprem
court
order
rule
natur
occur
gene
sequenc
could
patent
term
molecular
diseas
introduc
paul
colleagu
base
find
chang
singl
amino
acid
bglobin
chain
caus
sickl
cell
anaemia
principl
explor
set
foundat
molecular
diagnost
even
though
big
transform
occur
mani
year
later
correct
accur
identif
caus
agent
like
microb
microbi
diseas
particular
genet
sequenc
genet
diseas
protein
level
essenti
manag
patient
make
specif
sensit
import
tool
diagnosi
classic
molecular
techniqu
like
normal
pcr
blot
although
play
satisfactori
role
diagnosi
howev
current
molecular
techniqu
like
gene
peptid
sequenc
realtim
pcr
microarray
may
detect
precis
specif
without
consum
much
time
discoveri
pcr
quick
optim
thermo
stabl
taq
dna
polymeras
thermu
aquaticu
greatli
facilit
revolution
molecular
diagnost
robust
techniqu
larg
amount
copi
target
sequenc
gener
exponenti
amplif
permit
identif
known
mutat
within
singl
day
rather
month
advent
pcr
molecular
diagnost
cross
threshold
clinic
laboratori
provis
genet
servic
carrier
popul
screen
known
mutat
prenat
diagnosi
inherit
diseas
recent
year
identif
unknown
mutat
therefor
move
proper
environ
clinic
laboratori
molecular
diagnost
could
provid
servic
initi
consid
pcr
cycl
theoret
doubl
amount
specif
dna
sequenc
present
result
exponenti
accumul
dna
fragment
amplifi
pcr
enzymedriven
primermedi
forward
revers
primer
temperaturedepend
process
replic
specif
dna
sequenc
vitro
principl
pcr
base
repetit
cycl
three
simpl
reaction
amplif
includ
denatur
templat
dna
doubl
strand
separ
two
singl
strand
anneal
next
temperatur
reduc
two
specif
oligonucleotid
primer
attach
dna
templat
complementarili
extens
temperatur
rais
time
facilit
dna
polymeras
extend
primer
terminu
primer
synthes
complementari
strand
along
terminu
templat
dna
use
deoxynucleotid
contain
media
extens
lead
format
new
doubl
strand
dna
copi
compris
two
singl
templat
dna
strand
two
synthes
complementari
dna
strand
extens
reaction
repeat
step
copi
dna
serv
anoth
templat
amplif
pcr
product
doubl
cycl
n
cycl
approx
final
pcr
product
doubl
copi
templat
dna
theori
whole
process
need
h
depend
type
nucleotid
multiplex
pcr
like
perform
multipl
pcr
reaction
simultan
singl
pcr
tube
two
primer
pair
includ
one
reaction
tube
two
dna
templat
target
simultan
rel
effortless
molecular
way
detect
differ
bacteria
one
pcr
reaction
multiplex
pcr
primer
pair
specif
target
gene
pcr
product
amplicon
differ
size
specif
differ
dna
sequenc
techniqu
save
time
reagent
target
multipl
gene
time
therefor
extra
inform
may
gain
singl
testrun
otherwis
would
requir
sever
time
reagent
time
perform
anneal
temperatur
primer
set
must
optim
work
correctli
within
singl
reaction
amplicon
size
base
pair
length
differ
enough
form
distinct
band
visual
gel
electrophoresi
rtpcr
techniqu
synthesi
cdna
rna
revers
transcript
rt
firstli
follow
amplif
specif
cdna
pcr
valuabl
sensit
techniqu
mrna
detect
quantit
current
avail
rtpcr
mostli
use
detect
virus
viabil
microbi
cell
assess
microbi
mrna
discoveri
pcr
also
provid
foundat
design
develop
mani
mutat
detect
scheme
base
amplifi
dna
gener
pcr
either
use
gener
dna
fragment
examin
part
recognit
method
first
attempt
use
restrict
enzym
oligonucleotid
probe
immobil
onto
membran
solut
order
spot
exist
genet
variat
particular
sickl
cell
diseasecaus
mutat
follow
year
even
larger
number
mutat
detect
approach
build
implement
rtpcr
may
singl
step
two
step
procedur
name
suggest
singl
step
rtpcr
shall
combin
firststrand
cdna
synthesi
rt
subsequ
pcr
singl
reaction
tube
techniqu
requir
gene
specif
primer
use
high
throughput
applic
howev
less
sensit
effici
sinc
reaction
compromis
revers
transcript
amplif
condit
two
step
pcr
requir
two
stepsfirst
one
synthesi
cdna
pcr
tube
follow
second
step
separ
pcr
tube
amplif
gene
interest
techniqu
sensit
flexibl
allow
analysi
multipl
gene
real
time
pcr
simpl
quantit
assay
amplifi
dna
sequenc
illustr
first
time
higuchi
et
al
base
use
fluoresc
label
probe
detect
confirm
quantifi
pcr
product
gener
real
time
real
time
pcr
three
novel
featur
temperatur
cycl
occur
consider
faster
standard
pcr
assay
hybrid
specif
dna
probe
occur
continu
amplif
reaction
fluoresc
dye
coupl
probe
fluoresc
hybrid
take
place
lack
post
pcr
process
amplifi
product
make
techniqu
conveni
product
amplifi
product
observ
automat
real
time
monitor
fluoresc
depend
amount
target
gene
small
signal
produc
within
min
sinc
tube
open
time
reaction
risk
carri
contamin
get
consider
reduc
recent
year
commerci
autom
realtim
pcr
system
avail
light
cycler
taqman
system
light
cycler
tm
smart
cycler
system
perform
realtim
fluoresc
monitor
use
fluoresc
dye
sybrgreen
bind
nonspecif
doublestrand
dna
gener
pcr
amplif
other
taqman
use
floresc
probe
bind
specif
amplif
target
sequenc
techniqu
divid
roughli
three
categori
depend
basi
discrimin
allel
variant
first
restrict
enzym
base
approach
use
extens
rflp
analysi
exploit
alter
restrict
enzym
site
lead
gain
loss
restrict
event
sinc
number
enzymat
approach
mutat
detect
conceiv
base
depend
secondari
structur
primari
dna
sequenc
method
util
activ
resolvas
enzym
endonucleas
vii
recent
endonucleas
digest
heteroduplex
dna
form
anneal
wild
type
mutant
dna
mutat
indic
size
variou
fragment
variat
theme
involv
use
chemic
agent
purpos
anoth
enzymat
approach
mutat
detect
oligonucleotid
ligat
assay
techniqu
involv
hybrid
two
oligonucleotid
complementari
dna
stretch
site
possibl
mutat
oligonucleotid
primer
design
end
first
primer
immedi
adjac
end
second
primer
therefor
first
primer
match
complet
target
dna
primer
ligat
dna
ligas
hand
mismatch
occur
end
first
primer
ligat
product
obtain
categori
distinguish
number
differ
approach
intend
screen
known
unknown
mutat
base
differ
electrophoret
mobil
mutant
allel
denatur
nondenatur
condit
use
techniqu
singl
strand
conform
polymorph
sscp
heteroduplex
hda
analys
among
first
method
design
spot
molecular
defect
genom
loci
combin
capillari
electrophoresi
sscp
hda
analysi
provid
excel
simpl
rapid
mutat
detect
platform
low
oper
cost
fascinatingli
potenti
easili
autom
thu
allow
highthroughput
analysi
patient
dna
anoth
equal
well
employ
techniqu
mutat
detect
denatur
temperatur
gradient
gel
electrophoresi
dgge
tgge
respect
case
electrophoret
mobil
differ
wild
type
mutant
allel
visual
gradient
denatur
agent
urea
formamid
increas
temperatur
lastli
increasingli
use
mutat
detect
techniqu
twodimension
gene
scan
base
twodimension
electrophoret
separ
amplifi
dna
fragment
accord
size
base
pair
sequenc
latter
involv
dgge
follow
size
separ
step
set
techniqu
consist
foundat
presentday
mutat
detect
technolog
owe
extra
advantag
effortlessli
autom
henc
highli
recommend
high
throughput
mutat
detect
screen
break
nucleic
acid
hybrid
techniqu
base
pair
two
complimentari
nucleotid
strand
mainli
due
involv
hydrogen
thu
duplex
hybrid
result
hybrid
may
result
dnadna
rnarna
dnarna
thu
singl
strand
molecul
may
dna
rna
one
nucleic
acid
strand
probe
origin
organ
known
ident
strand
target
origin
unknown
organ
detect
identifi
saiki
et
al
develop
fast
accur
conveni
method
detect
known
mutat
revers
dotblot
implement
detect
bthalassemia
mutat
essenc
method
util
oligonucleotid
bound
membran
hybrid
target
amplifi
dna
techniqu
advantag
one
membran
strip
util
detect
mani
differ
known
mutat
singl
individu
one
stripon
patient
type
assay
potenti
autom
eas
interpret
result
use
classic
avidinbiotin
system
howev
disadvantag
techniqu
use
detect
unknown
mutat
continu
develop
given
rise
allelespecif
hybrid
amplifi
dna
pcraso
filter
newli
extend
dna
oligonucleotid
microarray
high
throughput
mutat
analysi
recent
petralia
et
al
report
point
care
real
time
pcr
platform
detect
pathogen
speci
hbv
core
platform
hybrid
microchip
compos
silicon
part
polycarbon
portion
mount
plastic
ring
experi
conduct
differ
anneal
temperatur
probe
amount
result
indic
improv
sensit
ct
microarray
batteri
enhanc
featur
microscop
techniqu
techniqu
usual
involv
hybrid
dna
target
molecul
quantit
gene
express
qualit
diagnost
analysi
larg
number
gene
simultan
genotyp
multipl
region
genom
dna
spot
contain
approx
picomol
mol
specif
dna
sequenc
known
probe
report
tremend
improv
microarray
technolog
term
effici
discriminatori
power
reproduc
sensit
specif
due
advanc
fabric
robot
bioinformat
improv
allow
transit
microarray
strictli
research
bench
site
bed
site
clinic
diagnost
applic
microarray
differenti
basi
characterist
natur
probe
solidsurfac
support
use
specif
method
use
probe
address
andor
target
detect
advanc
appear
form
insitusynthes
array
extremelyhighdens
microarray
use
oligonucleotid
probe
exampl
gene
chip
affymetrix
santa
clara
ca
wide
known
insitu
synthes
array
synthes
directli
surfac
microarray
made
cm
quartz
wafer
unlik
print
oligonucleotid
array
describ
situsynthes
probe
typic
short
bp
multipl
probe
per
target
includ
improv
sensit
specif
statist
accuraci
yet
anoth
type
bead
array
similar
mention
print
situhybrid
microarray
bead
array
illumina
san
diego
ca
provid
pattern
substrat
highdens
detect
target
nucleic
acid
howev
instead
glass
slide
silicon
wafer
direct
substrat
bead
array
reli
silica
bead
randomli
selfassembl
onto
one
two
avail
substrat
sentrix
array
matrix
sam
sentrix
bead
chip
unlik
array
exclus
featur
bead
array
reli
passiv
transport
hybrid
nucleic
acid
one
type
array
electron
microarray
util
activ
hybrid
via
electr
field
control
nucleic
acid
transport
microelectron
cartridg
nanochip
nanogen
san
diego
ca
use
complementari
metal
oxid
semiconductor
technolog
electron
address
nucleic
acid
nano
chip
cartridg
connector
control
individu
test
site
contrast
mention
array
base
suspens
bead
array
essenti
threedimension
array
base
use
microscop
polystyren
sphere
microspher
bead
solid
support
flow
cytometri
bead
target
detect
furthermor
distinct
highdens
illumina
bead
array
bead
immobil
fiberopt
strand
silicon
slide
clinic
diagnost
laboratori
chosen
expens
high
technolog
infrastructur
number
test
expect
perform
larg
enough
justifi
capit
outlay
therefor
simpl
screen
test
sscp
hda
still
method
choic
mani
clinic
laboratori
allow
rapid
simultan
detect
differ
sequenc
variat
detect
rate
close
although
pcr
significantli
facilit
expans
molecular
diagnost
nonetheless
number
limit
first
problemat
taq
polymeras
amplifi
cg
repeatrich
region
sometim
lead
classic
altern
southern
blot
analysi
also
taq
polymeras
errorpron
rang
nucleotid
strongli
influenc
condit
amplif
reaction
magnesium
deoxyribonucleotid
concentr
ph
temperatur
due
polymeras
error
unspecif
background
depend
detect
method
result
limit
detect
level
overcom
technic
problem
posit
result
confirm
altern
method
use
high
fidel
thermo
stabl
polymeras
final
need
stress
despit
wealth
mutat
detect
methodolog
dna
sequenc
technolog
immens
contribut
detect
unknown
mutat
late
determin
sequenc
nucleic
acid
contain
even
five
ten
nucleotid
extrem
difficult
labori
task
introduct
new
techniqu
dna
sequenc
includ
sever
method
technolog
use
determin
order
nucleotid
basesadenin
guanin
cytosin
thyminein
molecul
dna
knowledg
dna
sequenc
becom
indispens
basic
biolog
research
numer
appli
field
diagnost
biotechnolog
microbiolog
etc
signific
acceler
field
biolog
research
discoveri
advent
dna
sequenc
sever
microbi
genom
sequenc
use
techniqu
two
differ
method
sequenc
dna
develop
chain
termin
method
chemic
degrad
method
maxam
w
gilbert
develop
dna
sequenc
method
base
chemic
modif
dna
subsequ
cleavag
specif
base
rapidli
becam
accept
sinc
purifi
dna
could
use
directli
initi
sanger
method
requir
read
start
clone
product
singlestrand
dna
howev
improv
sanger
method
maxamgilbert
sequenc
less
popular
due
technic
complex
prohibit
use
standard
molecular
biolog
kit
extens
use
hazard
chemic
difficulti
scaleup
four
reaction
g
g
c
c
thu
seri
label
fragment
gener
radio
label
end
first
cut
site
molecul
size
base
separ
fragment
four
reaction
done
parallel
electrophoresi
denatur
acrylamid
gel
visual
done
exposur
gel
xray
film
autoradiographi
yield
seri
dark
band
correspond
radiolabel
dna
fragment
sequenc
may
infer
method
sometim
call
chemic
sequenc
method
chaintermin
method
frederick
sanger
method
becam
popular
method
dna
sequenc
due
greater
effici
use
fewer
toxic
chemic
lower
amount
radioact
method
maxam
gilbert
key
principl
sanger
method
use
dideoxynucleotid
triphosph
ddntp
dna
chain
termin
new
era
molecular
biolog
dawn
februari
first
draft
sequenc
human
genom
declar
intern
human
genom
sequenc
consortium
follow
genom
sequenc
organ
new
era
came
new
opportun
challeng
post
human
genom
draft
public
major
challeng
improv
exist
mutat
detect
technolog
achiev
robust
cost
effect
rapid
highthroughput
analysi
genom
variat
last
decad
technolog
improv
rapidli
new
mutationdetect
techniqu
becom
avail
wherea
old
methodolog
evolv
fit
increas
demand
autom
high
throughput
screen
denatur
high
perform
liquid
chromatographi
dhplc
use
detect
polymorph
chang
diseasecaus
mutat
one
new
technolog
emerg
detect
presenc
genet
variat
differenti
retent
homoand
heteroduplex
dna
reversedphas
chromatographi
partial
denatur
dhplc
prove
one
power
tool
mutat
detect
capabl
detect
singlebas
substitut
delet
insert
detect
success
uv
fluoresc
monitor
within
min
unpurifi
pcr
product
larg
base
anoth
use
techniqu
mutat
analysi
pyro
sequenc
nongelbas
genotyp
technolog
provid
reliabl
method
attract
altern
dhplc
pyrosequenc
detect
de
novo
incorpor
nucleotid
base
specif
templat
caus
releas
pyrophosph
convert
atp
follow
luciferas
stimul
light
produc
detect
charg
coupl
devic
camera
translat
pyrogram
nucleotid
sequenc
deduct
steadi
increas
number
sampl
sent
molecular
analysi
due
sensit
robust
techniqu
like
real
time
pcr
high
throughput
techniqu
like
microarray
among
variou
molecular
techniqu
discuss
use
pcr
molecular
diagnost
consid
gold
standard
detect
nucleic
acid
becom
essenti
tool
research
laboratori
wider
accept
realtim
pcr
due
improv
rapid
sensit
reproduc
real
time
detect
pcr
product
exponenti
phase
reaction
therebi
combin
amplif
detect
one
singl
step
reduc
number
cycl
use
fluorogen
label
sensit
method
detect
larg
remov
postpcr
detect
procedur
make
techniqu
sensit
current
newborn
screen
phenylketonuria
treatabl
genet
diseas
futur
might
see
children
high
risk
coronari
arteri
diseas
get
character
treat
prevent
chang
vascular
wall
earli
adulthood
near
futur
could
wit
part
standard
medic
practic
individu
drug
monitor
respons
profil
throughout
life
use
genet
test
identif
individu
dna
signatur
shortli
genet
test
compris
wide
spectrum
differ
analys
host
consequ
individu
famili
worth
emphas
explain
molecular
diagnost
public
clinic
laboratori
seen
boost
number
molecular
techniqu
find
util
diagnosi
monitor
diseas
condit
right
plasmid
profil
variou
method
gener
restrict
fragment
length
polymorph
polymeras
chain
reaction
pcr
microarray
made
increas
inroad
clinic
laboratori
among
molecular
techniqu
popular
one
character
etiolog
agent
diseas
directli
clinic
sampl
pcr
base
method
allow
rapid
detect
uncultur
fastidi
microorgan
directli
clinic
sampl
past
two
decad
relentless
progress
applic
molecular
diagnost
techniqu
open
new
vista
diagnosi
microbi
diseas
also
diseas
disord
like
neurodegen
disord
cancer
genet
diseas
variou
class
mrna
like
non
code
lnc
snc
micro
rna
genet
variant
variou
diseas
like
cancer
alzheim
parkinson
etc
identifi
character
may
use
manag
patient
present
use
dna
rna
microbi
character
identif
modif
tradit
probe
hybrid
fluoresc
situ
hybrid
fish
evolv
highli
valuabl
tool
specif
rapid
detect
pathogen
bacteria
clinic
sampl
without
cultiv
report
patient
exacerb
due
h
influenza
aureu
p
aeruginosa
fish
use
rapid
detect
microorgan
caus
acut
pulmonari
infect
sensit
phylogenet
identif
singl
cell
microb
success
done
base
upon
rrna
sequenc
sequenc
organ
fish
probe
complementari
specif
sequenc
rrna
detect
malaria
infect
blood
sampl
assay
highli
sensit
identifi
five
speci
plasmodium
known
caus
malaria
human
better
geimsa
stain
fish
techniqu
allow
develop
low
cost
molecular
test
like
dna
probe
method
detect
c
trachomati
n
gonorrhea
exampl
lowcost
molecular
test
hybrid
assay
innolipa
riftb
innogenet
genotyp
mtbdr
plu
hain
life
scienc
gmbh
lineprob
assay
display
pool
good
sensit
specif
detect
rifampin
resist
isol
directli
clinic
specimen
amplif
detect
signal
probe
hybrid
improv
sensit
low
gene
copi
per
micro
liter
provid
quantit
capabl
approach
wide
util
quantit
assay
viral
load
hepat
b
viru
hbv
hepat
c
viru
hcv
develop
dual
colour
fish
recent
allow
detect
tuberculosi
avium
pathogen
bacteri
cultur
high
sensit
rapid
pace
less
h
detect
time
fish
probe
commerci
avail
market
use
solutionphas
hybrid
chemiluminesc
direct
recognit
microbi
agent
sampl
materi
like
product
genprob
hybrid
captur
assay
system
digen
murex
system
flexibl
adapt
small
larg
number
specimen
simpl
handl
work
besid
long
shelf
life
product
help
detect
neisseria
gonorrhoea
chlamydia
trachomati
singl
specimen
one
specimen
two
separ
probe
hybrid
captur
system
identifi
human
papillomaviru
hpv
cervic
scrape
herp
simplex
viru
hsv
vesicl
materi
cytomegaloviru
cmv
blood
fluid
although
less
sensit
target
amplif
base
method
detect
virus
method
give
quantit
result
proven
fruit
determin
viral
load
prognosi
monitor
respons
therapi
probe
hybrid
use
identifi
slow
grow
organ
isol
cultur
use
either
liquid
solid
media
identif
mycobacteria
slowgrow
organ
dimorph
fungi
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
certainli
facilit
commerci
avail
probe
commerci
probe
recogn
organ
produc
genprob
use
acridinium
esterlabel
probe
direct
speciesspecif
rrna
sequenc
genprob
product
avail
cultur
identif
mycobacterium
tuberculosi
aviumintracellular
complex
gordona
kansasii
cryptococcu
neoforman
dimorph
fungi
n
gonorrhoea
staphylococcu
aureu
streptococcu
pneumonia
escherichia
coli
haemophilu
influenza
enterococcu
spp
agalactia
listeria
monocytogen
sensit
specif
probe
excel
provid
speci
identif
within
h
mycobacteri
probe
hand
accept
common
method
identif
tuberculosi
relat
speci
shah
et
al
success
util
mn
genusmtbc
mtbcmac
fish
assay
effect
diagnost
tool
detect
mycobacteria
solid
liquid
cultur
identif
mtbc
mac
ntm
mac
two
fish
assay
lod
least
cfu
bacilli
per
ml
help
minim
delay
diagnosi
applic
rel
earli
initi
cultur
et
al
use
pcr
amplif
combin
oligonucleotid
microarray
identifi
bacillu
anthraci
base
rrna
region
sever
studi
report
use
microarray
identifi
pathogen
yeast
mold
target
region
fungal
rrna
gene
recent
dna
microarray
establish
detect
identifi
commonli
encount
fungal
pathogen
clinic
specimen
collect
neutropen
patient
microarray
techniqu
detect
identif
enteropathogen
bacteria
speci
subspeci
level
develop
cover
pathogen
e
coli
vibrio
cholera
vibrio
parahaemolyticu
salmonella
enterica
campylobact
jejuni
shigella
spp
yersinia
enterocolitica
listeria
monocytogen
recent
studi
develop
new
oligonucleotid
microarray
compris
ident
subarray
simultan
rapid
detect
avian
virus
avian
influenza
viru
aiv
newcastl
diseas
viru
ndv
infect
bronchiti
viru
ibv
infecti
bursal
diseas
viru
ibdv
singleand
mixedviru
infect
diagnost
effect
develop
dna
microarray
therefor
prove
highli
effect
mass
survey
specif
detect
aiv
ndv
ibv
ibdv
circul
region
cours
epidemiolog
surveil
pcr
robust
techniqu
detect
minut
quantiti
specif
microbi
dna
sequenc
owe
abil
amplifi
minut
amount
less
copi
specif
microbi
dna
sequenc
background
mixtur
host
dna
mani
microorgan
identifi
use
techniqu
exampl
mycobacterium
tuberculosi
pneumococci
meningococci
burkholderia
cenocepacia
virus
known
caus
acut
viral
enceph
human
batteri
infect
state
cn
account
viral
infect
like
involv
spinal
cord
myeliti
brain
stem
eg
rhombenceph
cerebellum
cerebel
cerebrum
enceph
almost
acut
viral
infect
cn
produc
degre
mening
well
parenchym
inflamm
rare
west
nile
viru
wnv
meningoenceph
cytomegaloviru
cmv
radiculomyel
polymorphonuclear
cell
rather
lymphocyt
may
predomin
cell
type
thu
provid
diagnost
guidelin
even
divers
symptom
routin
csf
studi
rare
lead
identif
specif
etiolog
agent
entir
pictur
diagnosi
viral
infect
cn
chang
good
day
due
discoveri
new
molecular
diagnost
technolog
pcr
amplifi
viral
nucleic
acid
csf
realtim
multiplex
pcr
assay
design
research
extrem
rapid
permit
confirm
bacteri
isol
brucella
spp
b
abortu
b
melitensi
within
h
techniqu
assist
identif
infrequ
isol
brucella
speci
recognit
atyp
brucella
strain
util
genu
specif
primersprob
set
advantag
sinc
convent
method
brucella
isol
character
may
take
day
week
perform
often
requir
prepar
heavi
suspens
highli
infecti
pathogen
sinc
viral
diseas
sever
viral
load
link
use
realtim
pcr
quantit
proven
benefici
studi
role
viral
reactiv
persist
progress
diseas
nonetheless
gener
diagnosi
invas
diseas
caus
aspergillu
fumigatu
aspergillu
flavu
made
easier
realtim
pcr
assay
diagnosi
effluxmedi
resist
pseudomona
aeruginosa
perform
use
molecular
diagnost
approach
real
time
pcr
help
detect
mexa
mexx
revers
transcript
pcr
mex
c
mex
e
thu
help
analysi
multidrug
resist
p
aeruginosa
recent
jiang
et
al
develop
assay
combin
multiplex
pcr
luminex
technolog
mplt
detect
nine
import
respiratori
bacteri
pathogen
frequent
caus
lrti
includ
pneumonia
moraxella
catarrhali
aureu
streptococcu
pyogen
haemophilu
influenza
mycoplasma
pneumonia
legionella
spp
p
aeruginosa
klebsiella
pneumonia
assay
demonstr
high
diagnost
accuraci
pneumonia
sensit
specif
furthermor
sensit
specif
eight
pathogen
attain
diagnost
accuraci
inde
assay
may
promis
supplement
convent
method
use
diagnos
lrti
qualit
detect
hiv
nucleic
acid
find
applic
three
main
area
identif
acut
infect
assur
blood
safeti
earli
infant
diagnosi
shortcom
western
blot
analysi
confirm
hiv
infect
overcom
amend
test
algorithm
employ
qualit
nucleic
acid
test
aptima
rna
qualit
assay
procleix
assay
genprob
san
diego
ca
usa
food
drug
administr
fda
approv
blooddonor
screen
exclud
blood
donor
acut
hiv
infect
transcriptionmedi
amplif
technolog
use
two
assay
infant
born
mother
infect
matern
antibodi
direct
hiv
month
age
prevent
use
antibodybas
assay
earli
diagnosi
hiv
infect
infect
infant
high
morbid
mortal
first
year
life
thu
earli
diagnosi
import
establish
infect
statu
expos
infant
order
employ
appropri
art
suffici
earli
qualit
nucleic
acid
assay
detect
hiv
provir
dna
viral
rna
total
nucleic
acid
becom
method
choic
diagnosi
infant
born
mother
coba
ampliprepcoba
taqman
qualit
test
one
test
use
whole
blood
dri
blood
spot
direct
gag
ltr
region
genom
h
cell
number
hiv
rna
viral
load
two
routin
use
laboratori
marker
chronic
infect
patient
serv
guid
art
initi
monitor
treatment
effect
determin
clinic
progress
determin
treatment
regimen
hiv
rna
level
detect
limit
indic
excel
complianc
patient
art
efficaci
viral
load
determin
typic
perform
hiv
rna
amplif
revers
transcriptionpolymeras
chain
reaction
rtpcr
nucleic
acid
sequencebas
amplif
nasba
branch
chain
dna
test
new
microarray
techniqu
includ
affymetrix
santa
clara
ca
usa
current
allow
host
transcriptom
analys
individu
infect
studi
involv
microarray
yield
import
data
effect
gene
express
provid
new
insight
intric
interact
occur
infect
host
transcriptom
profil
may
prove
extrem
import
evalu
diseas
progress
prognosi
rnaseq
approach
use
deepsequenc
technolog
transcriptom
profil
add
precis
transcriptom
analys
genprob
aptima
rna
qualit
assay
molecular
assay
fda
approv
diagnosi
acut
infect
confirmatori
test
diagnos
sampl
test
reactiv
antibodi
commerci
avail
molecular
assay
develop
quantit
viral
load
assay
therapeut
monitor
current
avail
expens
highthroughput
format
sequenc
broad
rang
pcr
product
facilit
identif
almost
bacteri
speci
compar
result
sequenc
known
sequenc
genbank
databas
identif
unknown
bacteria
possibl
sequenc
rrna
becom
import
tool
use
microbi
detect
identif
algorithm
especi
unusu
noncultur
fastidi
slow
grow
pathogen
antibiot
administ
patient
thu
techniqu
help
combat
infecti
diseas
consist
detect
bacteria
specimen
would
prove
critic
diagnosi
futur
therapi
circumst
pcr
reliabl
assay
detect
microb
clinic
specimen
major
challeng
rapid
detect
identif
character
microbi
pathogen
lie
accur
recognit
trait
speci
sub
speci
genu
combin
trait
uniqu
specif
microbi
strain
increasingli
dna
base
assay
replac
convent
serotyp
base
method
rather
dna
base
assay
detect
known
genom
signatur
gener
rrnabas
almost
conserv
natur
offer
rapid
reliabl
identif
microbi
pathogen
precis
manner
new
dna
sequenc
platform
alreadi
enabl
novel
approach
explor
character
microbi
genom
time
profoundli
alter
understand
natur
genet
divers
exist
microbi
popul
tabl
repres
variou
establish
techniqu
current
use
screen
microbi
infect
worth
interact
basic
scienc
clinic
practic
close
associ
becom
even
appar
past
sixti
year
notabl
rate
develop
field
molecular
genet
trinucleotid
repeat
dna
sequenc
posit
within
transcrib
region
gene
expand
process
vibrant
mutat
like
due
mechan
strand
slippag
dna
replic
ultim
compromis
function
gene
dynam
mutat
cgg
triplet
give
rise
folatesensit
fragil
site
human
chromosom
primarili
fragil
site
clone
character
account
singl
common
form
inherit
mental
retard
fragil
x
syndrom
syndrom
clinic
welldefin
presenc
mental
retard
variabl
sever
modest
facial
dysmorph
macroorchid
adult
male
document
year
xlink
mendelian
disord
offer
abnorm
confus
featur
inherit
penetr
cytogenet
express
clinic
variabl
mainstream
male
carri
fragil
x
mutat
fraxa
exagger
mental
retard
show
cytogenet
induc
fragil
site
oblig
male
carrier
call
normal
transmit
male
clinic
cytogenet
neg
overal
characterist
defin
natur
fraxa
dynam
mutat
inactiv
fragil
x
mental
retard
gene
code
rnabind
protein
fmrp
typic
express
human
brain
testi
untransl
region
gene
harbor
seri
cgg
triplet
repeat
highli
polymorph
normal
individu
total
repeat
unit
vari
fraxa
mutat
demarc
premut
repeat
increas
beyond
uppernorm
limit
size
triplet
characterist
carrier
femal
normal
transmit
male
despit
structur
modif
gene
express
protein
function
alter
allel
transmit
premut
mother
offspr
scarc
ever
show
small
decreas
repeat
commonli
risk
higher
larger
premut
undertak
process
expans
reach
size
increas
repeat
refer
full
mutat
direct
molecular
diagnosi
fragil
x
syndrom
mark
discoveri
measur
abnorm
expans
cgg
repeat
region
character
state
methyl
promot
reflect
residu
function
gene
ration
intern
consensu
detail
dnabas
test
fraxa
mutat
skill
combin
use
two
techniqu
pcr
amplif
southern
blothybrid
tactic
commonli
select
adopt
molecular
analysi
fraxa
mutat
regularli
done
diagnost
servic
part
differ
diagnosi
mental
retard
unknown
caus
way
screen
southern
blot
genom
dna
digest
combin
restrict
enzym
includ
methylationsensit
rare
cutter
follow
hybrid
suitabl
label
probe
timeconsum
laborintens
procedur
may
accur
discrimin
small
premut
larg
normal
allel
use
test
sinc
ensur
reliabl
complet
diagnosi
mutat
gene
map
distal
end
short
arm
chromosom
found
account
von
hippellindau
diseas
highli
penetr
dominantli
inherit
syndrom
show
suscept
varieti
benign
malign
tumor
patholog
conclus
retin
central
nervou
system
hemangioblastoma
pheochromocytoma
renal
pancreat
cancer
von
hippellindau
diseas
sex
equal
involv
penetr
age
mean
age
diagnosi
year
thevhl
gene
bp
length
open
read
frame
orf
bp
two
infram
start
codon
compos
three
exon
exon
altern
splice
altern
transcript
ubiquit
express
tissuespecif
development
select
manner
studi
normal
function
tumor
suppressor
gene
promis
wide
gain
knowledg
mechan
gene
transcript
vhl
act
competitor
elongin
siii
one
transcript
elong
factor
modifi
vascular
endotheli
growth
factor
neoangiogenesi
upon
tumor
growth
depend
practic
approach
precis
find
medium
smallsiz
mutat
type
alter
commonli
found
vhl
pheochromocytoma
phenotyp
detect
done
procedur
pcr
amplif
partial
overlap
genom
dna
fragment
cover
entir
code
sequenc
vhl
gene
includ
exonflank
intron
region
amplif
product
subject
polyacrilamid
gel
electrophoresi
page
detect
deletioninsert
mutat
may
chang
molecular
weight
product
singl
strand
conform
polymorph
sscp
analysi
method
design
specif
identifi
singl
base
substitut
wide
use
mutat
scan
techniqu
base
tendenc
singl
strand
dna
molecul
assum
threedimension
conform
depend
primari
sequenc
specif
simpli
detect
nativ
polyacrylamid
gel
dna
fragment
show
size
alter
page
analysi
aberr
sscp
band
subsequ
subject
direct
autom
sequenc
confirm
character
mutat
strategi
allow
identifi
differ
mutat
unrel
vhl
patient
detect
case
somat
mosaic
asymptomat
subject
cystic
fibrosi
cf
common
autosom
recess
inherit
diseas
caucasian
affect
approxim
individu
multifacet
disord
influenc
pulmonari
pancreat
gastrointestin
reproduct
organ
system
patholog
process
influenc
organ
system
happen
due
mutat
cftr
gene
encod
cystic
fibrosi
transmembran
conduct
regul
membran
chlorid
channel
present
apic
membran
secretori
epithelia
cftr
protein
cyclicamp
depend
channel
activ
protein
kinas
occur
increas
level
camp
insid
secretori
epitheli
cell
ultim
bind
phosphoryl
site
regulatori
rdomain
cftr
protein
thu
open
channel
cftr
chlorid
channel
essenti
work
electrostat
attract
direct
intracellular
extracellular
anion
toward
posit
charg
transmembran
domain
insid
channel
cftr
protein
includ
transmembran
tm
domain
two
attract
bind
chlorid
andor
bicarbon
ion
bind
chlorid
ion
site
pore
mutual
repuls
hasten
expuls
ion
cell
cftr
activ
gener
chlorid
ion
secret
cell
addit
chlorid
ion
secret
epitheli
sodium
channel
enac
also
inhibit
cftr
konig
et
al
less
sodium
absorb
cell
maintain
higher
combin
ionic
gradient
allow
water
depart
cell
osmosi
provid
fluid
epitheli
tissu
secret
cystic
fibrosi
mucu
secret
becom
hypervisc
account
main
featur
cystic
fibrosi
individu
cftr
mutat
recent
time
report
caus
cf
http
wwwgenetsickkidsoncacftrapp
http
wwwhgmdcfacukacindexphp
inactiv
loss
function
mutat
includ
delet
insert
splice
site
mutat
nonsens
mutat
well
missens
mutat
sever
appear
diseas
may
depend
type
mutat
preliminari
investig
sampl
commonli
done
mean
commerci
avail
kit
gold
standard
routin
test
commerci
avail
kit
allow
analysi
approxim
sequenc
variant
account
cf
diseas
caus
mutat
mutat
test
capabl
identifi
least
mutat
eg
least
g
detect
requir
meticul
methodolog
attent
also
pinpoint
heterogen
state
patient
classic
form
cf
includ
posit
sweat
test
possibl
concern
less
case
addit
mutat
gene
encod
sodium
channel
enac
subunit
reveal
nonclass
cf
case
cftr
mutat
could
recogn
extens
mutat
scan
present
progress
molecular
diagnosi
unknot
sever
monogenet
multifactori
relationship
eye
diseas
segment
focu
common
genet
diseas
disord
known
caus
gene
avail
measur
prevent
treatment
glaucoma
well
document
heterogen
present
affect
popul
global
age
year
least
genet
loci
map
poag
loci
pcg
myocilin
myoc
optineurin
optn
wd
repeat
domain
cytochrom
describ
mutat
myoc
account
poag
case
european
american
studi
chines
popul
preval
myoc
mutat
optn
mutat
poag
patient
mutat
shown
french
pcg
patient
japanes
patient
addit
mutat
also
identifi
earlyonset
poag
wherea
myoc
mutat
link
pcg
studi
suggest
may
act
modifi
myoc
express
two
gene
may
interact
common
pathway
amd
reveal
progress
demolit
macula
lead
central
vision
loss
amd
approxim
affect
gener
popul
western
europ
stargardt
macular
dystrophi
stgd
common
hereditari
form
macular
degener
stgd
autosom
recess
less
often
domin
disord
retina
commonli
relat
earlyonset
macular
degener
three
contribut
gene
link
amd
complement
factor
h
cfh
atpbind
cassett
transport
apolipoprotein
e
apo
cfh
inform
main
gene
amd
one
mutat
cfh
found
relat
attribut
risk
amd
apo
allel
show
increas
risk
amd
confer
protect
role
amd
mutat
found
japanes
stgd
patient
rp
heterogen
group
retin
degener
often
affect
rod
photoreceptor
rp
caus
night
blind
loss
peripher
vision
eventu
loss
central
vision
preval
rp
estim
worldwid
rivolta
et
al
current
genet
loci
associ
nonsyndrom
rp
gene
recogn
rhodopsin
rho
mutat
identifi
adrp
case
mutat
retin
pigmentosa
account
adrp
case
retin
pigmentosa
gtpase
regul
rpgr
import
gene
xlrp
retinoblastoma
rb
predomin
intraocular
malign
children
famili
sporad
incid
live
birth
nearli
popul
rb
case
herit
gener
famili
bilater
unilater
multifoc
rb
observ
carrier
germlin
mutat
rb
transmit
autosom
domin
manner
penetr
secondari
genet
epigenet
chang
anoth
gene
necessari
precipit
tumor
develop
preval
rate
germlin
mutat
sporad
rb
chines
popul
among
unilater
case
direct
genet
test
achiev
sequenc
explor
nucleotid
sequenc
altern
approach
mutat
analysi
singl
strand
conform
polymorph
sscp
confirmationsensit
gel
electrophoresi
csge
denatur
highperform
liquid
chromatographi
dhplc
technic
procedur
also
util
cover
whole
spectrum
gene
mutat
fluoresc
situ
hybrid
fish
methylationspecif
polymeras
chain
reaction
pcr
present
taqman
probe
base
real
time
pcr
also
util
explor
nucleotid
sequenc
particular
locu
prenat
diagnosi
commonli
restrict
untreat
sever
congenit
eye
disord
rb
individu
famili
bilater
rb
genet
test
first
perform
peripher
blood
tumor
dna
known
code
exon
splice
boundari
promot
amplifi
pcr
follow
direct
sequenc
transmiss
spongiform
encephalopathi
tse
tse
prion
diseas
critic
disord
central
nervou
system
initi
unconvent
infecti
agent
prion
seemingli
contain
nucleic
acid
induc
specif
immunolog
reaction
host
lack
nucleic
acid
make
unsuit
use
pcr
real
time
techniqu
type
disord
variou
common
transmiss
spongiform
encephalopathi
cjd
creutzfeldtjakob
diseas
gss
syndrom
ffi
fatal
famili
insomnia
vcjd
variant
creutzfeldtjakob
diseas
scrapi
cwd
chronic
wast
diseas
bse
bovin
spongiform
encephalopathi
main
pathogenet
event
tse
conform
chang
host
protein
cellular
prp
prpc
encod
prion
gene
prnp
patholog
isoform
conform
call
prpsc
first
identif
experiment
scrapieinfect
rodent
aggreg
amyloid
fibril
accumul
neural
often
lymphoreticular
cell
although
blood
taken
vcjd
patient
inocul
suscept
mice
alway
caus
diseas
still
possibl
low
level
infect
consequ
prp
sc
might
present
blood
effici
speci
barrier
may
upset
manifest
numer
anim
studi
shown
pathogenesi
tse
experiment
inocul
rodentsmic
tse
agent
prp
sc
characterist
notic
cn
week
express
diseas
level
augment
anim
die
rise
prp
sc
correspond
infect
prp
sc
commonli
use
surrog
marker
assess
amount
infect
biolog
sampl
ratio
infect
prp
sc
rel
constant
hamster
brain
experiment
infect
k
strain
scrapi
mean
valu
protein
molecul
one
lethal
dose
recent
techniqu
preclin
level
suffici
potenc
prove
good
biomark
detect
low
level
protein
like
chemicophys
precipit
base
protocol
affin
chromatographi
affin
precipit
techniqu
amend
isol
method
prp
sc
sodium
phosphotungst
novel
molecul
plasminogen
bind
high
affin
prp
sc
might
enhanc
new
expect
preclin
diagnosi
tse
among
immunolog
method
prpsc
screen
western
blot
mainli
character
wide
valid
method
offer
advantag
recogn
differ
form
prpsc
analysi
molecular
mass
rel
abund
di
monoand
nonglycosyl
band
paramet
character
socal
prp
glycotyp
kind
prp
signatur
vari
among
differ
form
tse
prpsc
glycotyp
project
differenti
variou
form
tse
eg
scrapi
bse
sporad
variant
cjd
improv
classif
human
tse
sporad
cjd
exampl
combin
two
frequent
prpsc
glycotyp
ii
three
possibl
genotyp
prp
polymorph
codon
methionin
homozyg
valin
homozyg
heterozyg
enabl
sub
classif
form
six
distinct
group
present
distinct
clinic
patholog
featur
techniqu
time
consum
sampl
assess
time
elisa
overcom
problem
develop
gradat
immun
assay
form
dissociationenhanc
lanthanid
fluoresc
immunoassayconformationdepend
immunoassay
delfiacdi
latestgener
immunoassay
elisa
format
detect
system
sensit
timeresolv
lanthanid
fluoresc
instead
chemiluminesc
measur
picogram
g
prpsc
per
ml
thu
repres
one
sensit
techniqu
detect
prpsc
one
techniqu
muf
multispectr
ultraviolet
fluoresc
spectroscopi
character
protein
specif
fluoresc
pattern
emiss
excit
ultraviolet
radiat
bypass
need
pretreat
step
elimin
prpc
antibodi
bind
potenti
discrimin
cellular
patholog
prion
protein
variou
form
prpsc
differ
strain
moreov
sensit
specif
techniqu
use
fluoresc
antibodi
confoc
microscopi
fc
fluoresc
correl
spectroscopi
recogn
singl
fluoresc
molecul
solut
pass
excit
laser
beam
object
confoc
microscop
equip
singlephoton
counter
perform
quickli
requir
small
amount
sampl
assay
solut
mix
antiprp
antibodi
tag
fluorophor
bind
strongli
prpsc
aggreg
becom
highli
fluoresc
easili
visibl
background
monomer
prpc
techniqu
sensit
western
blot
abl
detect
first
time
prpsc
csf
cjd
patient
protein
also
detect
csf
patient
genet
cjd
carri
codon
codon
mutat
prnp
gene
csf
sampl
taken
patient
vcjd
protein
releas
csf
cerebr
damag
tau
neuronspecif
enolas
nse
also
increas
cjd
patient
although
specif
sensit
predict
valu
alway
inferior
equal
protein
genet
suscept
diseas
also
seen
sporad
iatrogen
cjd
affect
individu
homozyg
methionin
polymorph
site
prp
eurocjd
group
vcjd
patient
methionin
homozyg
suscept
howev
use
predict
develop
diseas
sinc
caucasian
popul
methionin
homozyg
eurocjd
group
find
prplike
gene
prndgene
locat
downstream
prp
gene
mammalian
speci
provid
hope
prnd
encod
protein
doppel
dpl
contribut
pathogenesi
tse
help
recognit
atrisk
individu
alzheim
agingrel
neurodegen
disord
demonstr
irrevers
loss
higher
cognit
function
patholog
hallmark
ad
includ
deposit
extracellular
amyloid
plaqu
cerebrovascular
amyloidosi
intracellular
neurofibrillari
tangl
nft
nft
made
hyperphosphoryl
microtubuleassoci
protein
tau
mapt
proteolyt
process
amyloid
beta
precursor
protein
app
gener
neurotox
ab
peptid
involv
format
neurit
amyloid
plaqu
recent
salvador
et
al
defin
sensit
method
biochem
diagnosi
ad
base
specif
detect
misfold
ab
oligom
abl
distinguish
ad
patient
control
individu
influenc
varieti
neurodegen
disord
degen
neurolog
diseas
overal
sensit
specif
protein
misfold
cyclic
amplif
assay
abpmca
util
function
properti
ab
oligom
seed
polymer
monomer
ab
abpmca
allow
detect
littl
fmol
ab
oligom
find
provid
proofofprincipl
basi
develop
highli
sensit
specif
biochem
test
ad
diagnosi
recent
studi
shown
reduc
express
novel
gene
potenti
microtubuleassoci
protein
involv
neuron
migrat
intracerebr
brainsitespecif
ad
tempor
lobe
vs
ad
occipit
lobe
polymeras
chain
reaction
pcr
select
cdna
suppress
subtract
hybrid
pcrcdnassh
express
analysi
addit
studi
also
valid
vitro
adrel
cell
model
amyloidb
peptid
ab
treat
neuron
reduc
express
correl
increas
tau
protein
phosphoryl
recent
zhang
et
al
discov
molecular
system
link
lateonset
alzheim
diseas
load
construct
generegulatori
network
postmortem
brain
tissu
load
patient
nondement
subject
show
load
reconfigur
specif
portion
molecular
interact
structur
thu
emphasis
immuneand
microgliaspecif
modul
domin
gene
involv
phagocytosi
contain
tyrobp
key
regul
regul
load
mous
microglia
cell
express
intact
truncat
tyrobp
reveal
express
chang
significantli
overlap
human
brain
tyrobp
network
advanc
molecular
biolog
improv
knowledg
primari
defect
basic
mechan
account
pathogenesi
numer
diseas
includ
cardiovascular
diseas
condit
phenotyp
express
process
new
approach
cardiac
diagnosi
formul
hcm
main
normal
famili
cardiac
diseas
character
complex
pathophysiolog
unlimit
heterogen
morpholog
function
clinic
cours
wide
divers
pinpoint
fact
hcm
may
seen
phase
life
newborn
elderli
clinic
cours
extrem
variabl
patient
remain
asymptomat
throughout
life
other
develop
sever
symptom
heart
failur
die
prematur
either
suddenli
often
absenc
prior
symptom
owe
progress
heart
failur
mark
even
preliminari
descript
diseas
hcm
commonli
inherit
mendelian
autosom
domin
trait
hcm
caus
mutat
gene
encod
protein
cardiac
sarcomer
bmyosin
heavi
chain
chromosom
cardiac
troponin
chromosom
chromosom
atropomyosin
chromosom
cardiac
myosinbind
protein
c
chromosom
moreov
mutat
gene
encod
crucial
regulatori
myosin
light
chain
report
may
extrem
rare
form
hcm
genet
divers
compound
intragen
heterogen
total
individu
diseasecaus
mutat
identifi
gene
avail
data
support
mutat
bmyosin
heavi
chain
gene
myosin
primari
contractil
protein
thick
filament
myofibril
may
respons
much
famili
hcm
known
genet
myosin
defect
prove
missens
mutat
cardiac
troponin
mutat
respons
estim
famili
hcm
troponin
bind
troponin
complex
tropomyosin
play
major
role
calcium
regul
cardiac
contract
relax
longqt
syndrom
lqt
romanoward
rare
famili
diseas
transmit
autosom
domin
trait
caus
predisposit
syncop
sudden
cardiac
death
often
relat
emot
physic
stress
vigor
activ
arous
stimuli
unexpect
collaps
mediat
ventricular
tachi
arrhythmia
polymorph
ventricular
tachycardia
torsad
de
point
ventricular
fibril
present
three
key
lqt
gene
provid
explan
approxim
disord
major
lqt
genotyp
genotypephenotyp
correl
genespecif
arrhythmogen
trigger
electrocardiogram
ecg
pattern
respons
therapi
intragen
increasingli
mutationspecif
risk
stratif
minor
lqtssuscept
gene
collect
account
less
lqt
case
key
diagnost
phenotyp
hallmark
lqt
abnorm
prolong
ventricular
depolar
measur
lengthen
qt
interv
ecg
marfan
syndrom
mf
system
connect
tissu
disord
autosom
domin
inherit
first
show
antoin
marfan
life
expect
may
reduc
usual
due
involv
cardiovascular
system
progress
aortic
root
dilat
dissect
ruptur
valvular
regurgit
primari
defect
respons
mf
first
describ
resid
gene
local
long
arm
chromosom
encod
connect
tissu
protein
fibrillin
structur
glycoprotein
compon
microfibril
extracellular
compon
particip
format
matur
elast
fiber
provid
structur
function
independ
elastin
linkag
analysi
shown
locu
heterogen
mf
causeandeffect
relat
clinic
marfan
phenotyp
confin
fibrillin
mutat
enigma
carcinogenesi
streamlin
signific
hallmark
sustain
prolif
signal
evad
growth
suppressor
resist
cell
death
enabl
replic
immort
induc
angiogenesi
activ
invas
metastasi
underli
hallmark
genom
instabl
gener
genet
divers
expedit
acquisit
thu
persist
progress
molecular
research
quit
simplifi
puzzl
although
pathogenesi
still
infanc
variou
cancer
cancer
chang
cellular
process
caus
tumour
grow
control
cancer
cell
sometim
mutat
oncogen
kra
bcatenin
analyz
molecular
signatur
cancer
cell
dna
level
express
via
messeng
rna
enabl
physician
character
cancer
choos
best
therapi
patient
assay
incorpor
array
antibodi
specif
protein
marker
molecul
emerg
technolog
hope
multiplex
assay
could
measur
mani
marker
global
prostat
cancer
pca
one
commonest
cancer
men
influenc
global
burden
prostat
biopsi
remain
invas
method
detect
pca
like
other
current
serum
prostatespecif
antigen
psa
consid
one
best
avail
tumour
marker
detect
pca
earli
stage
also
prognost
valu
howev
certain
limit
psa
signific
one
prostatespecif
cancer
specif
past
thirti
year
epigenet
broaden
field
play
import
role
studi
cancer
genet
epigenet
gene
regul
denot
noncod
herit
chang
gene
express
includ
dna
methyl
histon
modif
noncod
rnainduc
transcript
chang
desir
transcript
regul
genom
stabil
two
histon
modifi
hat
hdm
promis
pca
biomark
shown
express
pca
express
level
precis
link
differ
diseas
stage
characterist
may
make
standard
dual
biomark
hypermethyl
gene
silenc
document
cell
cycl
regul
anaphas
promot
complex
apc
ra
associ
domaincontain
protein
detoxif
enzym
eg
glutathion
stransferas
pi
furthermor
combin
assay
apc
hyper
methyl
unlimit
potenti
detectingpca
clinic
sampl
sensit
risk
pca
also
evalu
singl
nucleotid
polymorph
snp
allel
differ
region
chromosom
thada
eefsec
cmyc
msmb
bik
influenc
behavior
diseas
progress
chang
express
mrna
protein
explor
document
patient
patient
noncod
rna
ncrna
rel
novel
field
pca
research
term
ncrna
encompass
wellstudi
function
rna
like
rrna
trna
well
microrna
mirna
previous
known
small
ncrna
includ
long
ncrna
lncrna
small
interf
rna
sirna
three
known
lncrna
valid
signific
detect
screen
monitor
pca
high
specif
sensit
pca
non
code
prostatespecif
gene
pca
antigen
also
refer
differenti
display
recent
also
propos
gene
encod
lncrna
highli
prostatespecif
moreov
screen
fusion
tef
techniqu
examin
immunohistochemistri
fish
rt
pcr
found
signific
diagnosi
pca
howev
te
fusion
combin
mrna
may
prove
benefici
diagnosi
circul
microrna
mirna
newli
suppos
biomark
noninvas
diagnosi
variou
tumor
sever
gene
express
studi
also
report
alter
interleukin
expressionin
prostat
cancer
patient
differenti
regul
mirna
lead
chang
express
activ
target
pca
mirna
express
chang
develop
progress
pca
cancerrel
gene
regul
thu
dysregul
signific
pca
use
mous
xenograft
model
mitchel
et
al
demonstr
mirna
origin
human
pca
xenograft
enter
circul
thu
report
regul
sera
metastat
pca
patient
distinguish
pca
patient
healthi
control
high
sensit
accuraci
proteom
also
play
dynam
role
field
biomark
special
noninvas
collect
bio
fluid
prognosi
cgrp
vegf
endoglin
chromogranina
neuronspecif
enolas
transform
growth
factorb
methyl
gene
includ
apc
prostatespecif
cell
antigen
testosteron
estrogen
sex
hormon
bind
globulin
ecadherin
bcatenin
tissu
inhibitor
mmp
timp
progastrinreleas
peptid
progrp
zag
prostasom
autoantibodi
huntingtin
interact
protein
autoantibodi
leptin
human
kallikrein
amethylacylcoa
racemas
autoantibodi
earli
prostat
cell
hypermethyl
cytokin
macrophag
mif
apolipoprotein
aii
diagnosi
urokinasetyp
plasminogen
activ
system
prostat
membranespecif
antigen
hepatocyt
growth
factor
egfr
famili
egfr
shown
uniqu
potenc
diagnosi
well
prognosi
recent
dwivedi
et
al
propos
circul
serum
diagnost
biomark
prognosi
metastat
castrat
resist
pca
mcrpca
metastasi
associ
wide
explor
role
pca
mainli
vascular
progress
tumor
signific
mapk
pathway
member
ar
variou
androgen
metabol
gene
also
express
metastat
pca
cfo
jun
b
downregul
thu
also
signific
biomark
promis
molecular
marker
cancer
reportedli
express
human
kallikreinrel
peptidas
earli
pca
antigen
epca
amethylacylcoa
racemas
amacr
insulinlik
growth
factor
bind
protein
elev
circul
level
receptor
urokinas
plasminogen
activ
upa
receptor
upar
enhanc
zest
homolog
prostatespecif
membran
antigen
psma
breast
cancer
foremost
public
health
issu
global
number
new
case
femal
breast
cancer
per
women
per
year
number
death
per
women
per
year
rate
ageadjust
base
case
death
nation
cancer
institut
stat
report
http
seercancergov
statfactshtmlbreasthtml
typic
approach
breast
cancer
diagnost
via
hormon
receptor
analysi
ihc
ihc
involv
use
antibodi
enzym
horseradish
peroxidas
stain
tissu
section
tumor
antigen
interest
analysi
method
perform
either
frozen
formalinfix
paraffinembed
ffpe
tissu
well
small
amount
tissu
acquir
procedur
core
biopsi
ihc
also
advantag
determin
percentag
posit
nuclei
also
intens
stain
individu
nuclei
unfortun
addit
lack
inter
laboratori
standard
ihc
techniqu
process
character
posit
either
er
pr
stain
perform
subject
pathologist
therebi
introduc
variabl
interpret
regardless
subject
stain
intens
ihc
far
common
approach
evalu
hormon
statu
breast
cancer
today
anoth
major
prognost
marker
current
recommend
evalu
primari
invas
breast
cancer
human
epiderm
growth
factor
receptor
also
known
oncogen
belong
egf
receptor
egfr
famili
gene
amplif
shown
occur
primari
tumor
protein
express
found
almost
breast
cancer
effort
expand
avail
method
analysi
monogram
bioscienc
recent
releas
hermark
tm
breast
cancer
assay
assay
measur
total
protein
function
homodim
level
cell
surfac
ffpe
breast
cancer
tissu
practic
dual
antibodi
system
fluoresc
tag
one
antibodi
cleav
second
antibodi
contain
photoactiv
molecul
fluoresc
tag
quantifi
use
capillari
electrophoresi
ce
hermark
report
whether
patient
posit
equivoc
base
quantifi
protein
level
express
numer
valu
hermark
monogram
bioscienc
inc
wwwhermarkassay
com
thero
hism
molecular
diagnost
test
assess
ratio
gene
express
predictor
clinic
outcom
breast
cancer
patient
treat
tamoxifen
high
level
express
twogen
ratio
associ
tumor
aggress
failur
respond
tamoxifen
thero
mgism
addit
test
use
fivegen
express
index
stratifi
er
breast
cancer
patient
high
low
risk
recurr
reclassifi
intermedi
prolif
tumor
grade
grade
outcom
mamma
print
test
molecular
diagnost
tool
evalu
breast
cancer
patient
chanc
tumor
recurr
mamma
print
use
signatur
report
independ
prognost
valu
clinicopatholog
risk
assess
patient
nodeneg
breast
cancer
test
need
fresh
sampl
least
mm
diamet
obtain
surgic
biopsi
sent
agendia
laboratori
amsterdam
rnastabil
solut
analysi
rna
isol
sampl
amplifi
hybrid
standard
refer
mamma
print
microarray
obtain
express
profil
method
shown
extrem
high
correl
prognost
predict
tumor
recurr
p
us
fda
approv
mamma
print
test
use
freshli
frozen
tissu
although
mamma
print
gene
express
profil
potenti
use
diagnost
tool
mani
limit
need
taken
consider
oncotyp
dx
express
assay
use
qrtpcr
microarray
technolog
character
patient
may
posit
treat
chemotherapi
estim
likelihood
invas
breast
cancer
recur
treatment
oncotyp
dx
assay
use
ffpe
tissu
block
ship
anywher
usa
intern
current
oncotyp
dx
standard
breast
cancer
screen
test
women
earlystag
stage
ii
nodeneg
er
invas
breast
cancer
assay
report
recurr
score
rang
indic
probabl
cancer
recur
within
year
origin
diagnosi
recurr
score
categor
one
three
group
low
intermedi
high
risk
particular
urgenc
inform
women
earlystag
breast
cancer
great
varieti
treatment
option
narrow
tailor
patient
asco
nation
comprehens
cancer
network
nccn
incorpor
oncotyp
dx
assay
guidelin
microrna
deregul
breast
cancer
primarili
describ
iorio
colleagu
sinc
first
studi
surg
data
ad
express
variou
microrna
role
breast
cancer
surfac
multipl
studi
consist
signific
increas
express
breast
cancer
cell
line
human
tissu
compar
normal
cell
tissu
addit
one
three
microrna
iorio
et
al
studi
demonstr
signific
regul
breast
cancer
cell
compar
primari
human
mammari
epitheli
cell
hmec
howev
success
studi
appear
highli
express
metastat
cancer
cell
function
studi
describ
express
promot
cell
migrat
invas
vitro
initi
tumor
invas
metastasi
vivo
multipl
studi
also
demonstr
signific
associ
express
express
estrogen
receptor
breast
cancer
iorio
et
al
first
show
express
rais
tumor
er
first
report
microrna
profil
studi
significantli
regul
breast
cancer
comput
analysi
confirm
target
site
utr
region
microrna
matti
et
al
tissu
cultur
analysi
show
overexpress
cancer
cell
line
suppress
transcript
protein
level
decreas
cell
motil
invas
recent
advanc
investig
field
liquid
biopsybas
biomark
especi
dtc
ctc
bear
molecular
signatur
capabl
behav
potenti
biomark
discrimin
breast
cancer
local
metastas
one
current
project
serbnpdf
dst
new
delhi
also
show
uniqu
trend
variou
mirna
cancer
stem
cell
breast
cancer
patient
lung
cancer
major
caus
cancerrel
death
world
nonsmal
cell
lung
carcinoma
nsclc
explain
lung
cancer
lung
adenocarcinoma
typic
histolog
type
unit
state
enhanc
knowledg
molecular
alter
multipl
level
genet
epigenet
protein
express
function
import
potenti
impact
lung
cancer
diagnosi
prognost
treatment
lung
cancer
malign
tumourigenesi
narrat
activ
growth
promot
protein
eg
kirsten
rat
sarcoma
viral
oncogen
homolog
kra
epiderm
growth
factor
receptor
egfr
braf
met
alk
rearrang
transfect
ret
well
inactiv
tumour
suppressor
gene
eg
phosphatas
tensin
homolog
pten
lung
cancer
extrem
complex
genom
recent
larg
scale
exom
sequenc
studi
nonsmal
cell
lung
cancer
nsclc
identifi
mutat
gene
previous
describ
literatur
cosmic
databas
genom
studi
establish
previous
wellknown
alter
lung
cancer
kra
egfr
braf
also
identifi
low
frequenc
recurr
mutat
novel
lung
cancer
includ
potenti
target
alter
ret
fibroblast
growth
factor
receptor
discoidin
domain
receptor
lung
cancer
mutat
recogn
kirsten
rat
sarcoma
viral
oncogen
homolog
kra
epiderm
growth
factor
receptor
egfr
braf
parallel
phosphatidylinositol
k
pathway
oncogen
recent
mek
structur
rearrang
alk
possibl
rearrang
transfect
ret
provid
new
therapeut
target
amplif
anoth
mechan
activ
oncogen
met
adenocarcinoma
fibroblast
growth
factor
receptor
discoidin
domain
receptor
scc
role
tumour
suppressor
gene
increasingli
recogn
aberr
report
pten
occurr
molecular
target
label
defin
characterist
nsclc
egfr
mutat
alk
rearrang
clinic
relev
present
preval
mutat
vari
lung
cancer
aris
patient
differ
region
activ
egfr
mutat
found
caucasian
asian
popul
egfr
mutat
present
patient
nsclc
ethnic
differ
nsclc
properti
seem
limit
presenc
activ
egfr
mutat
also
evid
driver
oncogen
mutat
profil
includ
alk
kra
met
etc
histolog
henc
tumour
respons
target
therapi
treatment
presenc
driver
mutat
normal
found
mutual
exclus
other
tumour
lung
adc
among
asian
alk
rearrang
seen
patient
lung
adc
base
current
report
therapeut
molecular
target
egfr
mutat
alk
gene
rearrang
nsclc
avail
correspond
target
agent
algorithm
test
molecular
target
nsclc
propos
signifi
stepwis
approach
test
individu
target
begin
egfr
neg
alk
fusion
gene
potenti
target
appropri
among
nsclc
adenocarcinoma
account
histolog
subtyp
previou
report
correl
histolog
subtyp
adc
demonstr
micropapillari
featur
presenc
activ
egfr
mutat
lead
suggest
presenc
specif
mutat
nsclc
fact
repres
heterogen
cancer
biolog
also
respons
therapi
given
heterogen
lung
cancer
histolog
howev
histolog
subtyp
hard
use
sole
reliabl
marker
guidanc
molecular
phenotyp
select
target
therapi
target
therapeut
oncogen
mutat
like
egfr
alk
give
dramat
initi
treatment
respons
least
initi
stabl
clinic
diseas
oral
cancer
among
common
cancer
worldwid
particularli
seen
disadvantag
elderli
male
earli
detect
quick
treatment
provid
best
chanc
cure
predict
molecular
marker
thu
far
avail
assess
oscc
develop
includ
tsg
protein
express
chromosom
polysomi
dna
ploidi
chang
term
loss
heterozygos
loh
chromosom
probabl
due
chang
tsg
practis
biomark
adjunct
routin
histopatholoig
assess
may
help
prognost
effect
manag
pml
routin
use
still
hinder
cost
complex
test
lack
facil
laboratori
limit
outcom
studi
date
readili
avail
marker
cell
prolifer
antigen
apoptosi
bax
may
also
play
diagnost
role
apoptot
express
decreas
significantli
dysplast
earli
invas
lesion
increas
almost
normal
tissu
level
consequ
stage
express
increas
sharpli
initi
stage
oscc
significantli
decreas
later
stage
brush
biopsi
util
small
nylon
brush
gather
cytolog
sampl
sent
comput
scan
analysi
oral
cdx
identifi
display
individu
cell
suspect
cell
identifi
pathologist
examin
determin
final
diagnosi
sampl
judg
cancer
printout
abnorm
cell
comput
display
written
pathologist
report
return
clinician
recommend
posit
result
follow
convent
incision
biopsi
techniqu
prove
rather
controversi
concern
larg
relat
question
fals
neg
result
first
publish
studi
patient
usa
brush
biopsi
reportedli
detect
correctli
case
oscc
even
dentist
suspect
presenc
cancer
lesion
trial
show
multicent
conveni
sampl
lesion
biopsi
inadequ
specimen
exclud
analysi
us
studi
brush
biopsi
result
compar
scalpel
biopsi
histolog
determin
posit
predict
valu
abnorm
brush
biopsi
find
show
patient
abnorm
brush
biopsi
prove
posit
either
dysplasia
carcinoma
neg
either
dysplasia
carcinoma
give
posit
predict
valu
abnorm
brush
biopsi
promot
hypermethyl
pattern
tsg
deathassoci
protein
kinas
character
saliva
head
neck
cancer
patient
forens
scienc
sinc
shown
saliva
contain
number
messeng
ribonucl
acid
mrna
fragment
includ
salivari
specif
statherin
histatin
prolinerich
protein
well
ubiquit
express
spermidin
acetyl
transferas
sat
bactin
dehydrogenas
gapdh
mrna
saliva
bactin
sat
rel
stabl
despit
presenc
salivari
ribonucleas
mrna
saliva
test
saliva
sampl
oscc
patient
healthi
peopl
signatur
alway
present
higher
level
saliva
oscc
patient
saliva
healthi
peopl
overal
accuraci
rate
four
salivari
mrna
olfebf
associ
zinc
finger
protein
oaz
sat
collect
discriminatori
power
sensit
specif
oscc
detect
seven
mrna
molecul
transcript
interleukin
play
role
angiogenesi
replic
calciummedi
signal
pathway
cell
adhes
chemotaxi
cell
cycl
arrest
immun
respons
interleukin
take
part
signal
transduct
prolifer
inflamm
apoptosi
dual
specif
phosphatas
role
protein
modif
signal
transduct
oxid
stress
histon
famili
dna
bind
activ
ornithin
decarboxylas
antizym
take
part
polyamin
biosynthesi
calcium
bind
protein
p
role
protein
bind
calcium
ion
bind
sat
spermidin
spermin
take
part
enzym
transferas
activ
found
significantli
elev
oscc
patient
rather
healthi
control
genet
becom
drive
forc
medic
research
readi
integr
medic
practic
human
genom
draft
bioinformat
advanc
current
techniqu
open
new
vista
field
novel
therapeut
pharmacogenom
nutrigenom
may
transform
manag
untreat
diseas
disord
larg
patient
popul
size
medicin
drug
advantag
mani
patient
often
flop
work
patient
moreov
work
may
caus
advers
side
effect
even
death
small
number
patient
although
larg
individu
variabl
drug
efficaci
safeti
known
exist
sinc
establish
human
medicin
caus
beyond
knowledg
hand
request
overcom
variat
receiv
consider
draft
human
genom
ever
human
genom
sequenc
offer
special
record
human
evolut
vari
among
popul
individu
sequenc
variat
drug
target
protein
drugmetabol
enzym
drug
transport
alter
drug
efficaci
drug
side
effect
caus
variabl
drug
respons
individu
patient
prospect
avail
complet
human
genom
sequenc
made
possibl
analys
influenc
variat
human
genom
sequenc
pathogenesi
signific
diseas
respons
drug
therapi
acceler
rate
recent
year
fast
buildup
knowledg
genomediseas
genomedrug
interact
also
encourag
transform
pharmacogenet
new
entiti
human
genet
pharmacogenom
time
provid
rational
hope
individu
medicin
achiev
near
futur
util
high
throughput
genotyp
tool
character
screen
singl
nucleotid
polymorph
snp
ultim
lead
determin
uniqu
molecular
signatur
individu
rel
short
period
time
predict
suscept
risk
diseas
doubl
mutat
transvers
g
transit
often
present
patient
chronic
hepat
hepatocellular
carcinoma
hepat
less
often
asymptomat
carrier
immunosuppress
patient
carrier
without
hbv
marker
individu
drug
respons
forecast
known
genet
varianc
correl
drug
effect
like
drug
respons
maraviroc
efficaci
depend
allel
infect
interferonalpha
drug
efficaci
also
decid
allel
hepat
c
infect
thu
allow
physician
decid
patient
select
drug
treatment
pharmaceut
compani
research
develop
agenc
develop
precis
haplotyp
scheme
identifi
individualspati
benefit
type
drug
particular
diseas
disord
nutrigenom
also
evolv
promis
better
manag
patient
sever
bioactiv
food
compon
includ
essenti
nonessenti
nutrient
regul
gene
express
pattern
thu
nutrigenom
provid
effect
ingest
nutrient
food
compon
gene
express
gene
regul
ie
dietgen
interact
order
spot
dietet
compon
benefici
detriment
health
effect
nutrit
genom
nutrigenom
junction
health
diet
genom
influenc
via
epigenet
transcriptom
proteom
process
biolog
thu
help
determin
individu
nutrit
requir
base
genet
makeup
person
person
diet
well
associ
diet
chronic
diseas
like
cancer
open
new
vista
understand
complex
variou
diseas
upcom
year
molecular
diagnost
continu
critic
import
public
health
worldwid
molecular
diagnost
offer
physician
critic
inform
base
earli
explor
pathogen
subtl
chang
patient
gene
chromosom
allow
earlier
diagnosi
select
appropri
therapi
monitor
diseas
progress
wide
rang
molecular
base
test
avail
evalu
dna
differ
chang
gene
express
patient
dna
rna
realtim
pcr
fish
sequenc
technolog
complex
relationship
diseas
like
fertil
obes
metabol
syndrom
cancer
also
gain
momentum
due
explor
common
pathway
becom
possibl
due
advanc
molecular
techniqu
howev
mani
obstacl
overcom
execut
test
clinic
laboratori
test
employ
choic
technolog
equip
issu
costeffect
accuraci
reproduc
ie
robust
personnel
train
etc
current
pcrbase
test
outweigh
howev
altern
technolog
aim
explor
genom
complex
without
pcr
anticip
gain
momentum
come
year
sequenc
devic
costli
present
furthermor
develop
integr
silicon
chip
mount
biomolecul
go
chang
concept
tradit
wet
lab
labonachip
thu
would
possibl
analys
thousand
genesprotein
hour
low
amountsingl
cell
sampl
thu
come
era
revolutionari
go
chang
diagnost
system
also
plan
treatment
therapi
